BioSpace

Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program

BOSTON, Jan. 15, 2026 /PRNewswire/ -- Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the ...
The Washington Post

New federal spending bill for D.C. seeks to prevent repeat of 2025’s $1B cut

Good news from Congress has been hard to come by for D.C. officials over the past year. But a bipartisan spending bill released Sunday evening contains a number of bright spots for the city that top ...
Yahoo

SC students booted from K-12 voucher program spent $64K. The problem didn’t repeat, report says

Add Yahoo as a preferred source to see more of our stories on Google. A new national school voucher program allocates up to $1,700 in federal tax credits for individuals who donate to organizations ...
TMCnet

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program ...